Петлевые диуретики в практике терапевта

Литература
1. Преображенский Д.В, Сидоренко Б.А. Дифференциальная медикаментозная терапия при артериальной гипертензии. Сonsilium Medicum. 2001; 3 (10): 83.
2. Преображенский Д.В., Сидоренко Б.А., Шатунова И.М и др. Место диуретиков в лечении АГ. М.: Индап, 2000.
3. Горбунов В.М., Оганов Р.Г. «Торасемид – петлевой диуретик с особыми свойствами» Кардиоваскул. терапия и профилактика. 2006; 5 (5).
4.  Achhammer I, Metz P. Low dose loop diuretics in essential hypertension: Experience with torasemide. Drugs 1991; 41(suppl. 3): 80–91.
5. Porcellati C, Verdecchia P, Schillaci G et al. La torasemide, nuovo diuretico del’ansa, nell trattamento dell’ipertensione ar-teriosa: Studio con trolla to in doppla cecita. BasRazion Terapia 1990; 20: 407–10.
6. Baumgart P, Walger P, von Eiff M et al. Long-term efficacy and tolerance of torasemide in hypertension. In: Progress in pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart. 1990; 8: 169–81.
7. Spannbrucker N, Achhammer I, Metz P et al. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res 1988; 38 (1): 190–3.
8. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihyper-tensive monopharmacotherapy in elderly patients; randomized and double-blind study. In: Progress in Pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart. 1990; 8: 183–209.
9. Boelke T, Piesche L. Influence of 2,5-5 mg torasemide o.d. versus 25–50 mg HCTZ/50–100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Excerpta Medica. Amsterdam. 1993; 279–82.
10. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothi-azide o.d. In: Progress in Pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart. 1990; 8: 211–20.
11. Boelke T, Achhammer I, Meyer-Sabellek WA. Blutdrucksenkung und metabolische Veranderungen bei essentiellen Hypertonikem nach Langzeitgabe unterschiedlicher Diuretika. Hochdruck 1990; 9: 40–1.
12. Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs of today 1994; 8: 1–28.
13. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 3-е изд. М., 2005; с. 15–27.
14. Patterson J, Adams K, Applefeld M et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 1994; 14 (5): 514–21.
15. Cosin J, Diez J and TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507–13.
16. Muller K, Gamba G, Jaquet F et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail 2003; 5 (6): 793–801.
17. Murray M, Deer M, Ferguson J et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; (111): 513–20.
18. Spannheimer A, Muller K, Falkenstein P et al. Long-term diuretic treatment in heart failure: are there differences between furo-semide and torasemide? Schweiz Rundsch Med Prax 2002; 91 (37): 1467–75.
19. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. ДиУретическая терапия Эффективными дозами перораЛьных диуретиков торасемида (диувера) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ–ХСН). Сердечная недостаточность. 2011; 1 (63): 3–10.
20. Vargo DL, Kramer WG, Black PK et al. Bioavailiability, pharmacokinetics and pharmacodynamics of torsemide and fu-rosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57 (6): 601–9.
21. Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005). The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology.
22. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of chronic heart Failure in the Adult.
23. Risler T, Kramer B, Muller G. The efficacy of diuretics in acute and chronic renal failure. Focus on torasemide. Drugs 1991; 41: (suppl. 3): 69–79.
24. Kult J, Hacker J, Glocke M. Comparison of efficacy and tolerance of different oral doses of torasemide and furosemide in patients with advanced chronic renal failure. Arznt-Forsch/Drug Res 1998; 38: 212–4.
25. Vasavada N, Saha C, Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int 2003; 64 (2): 632–40.
26. Gerbes A, Bertheau-Reitha U, Falkner C et al. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial. J Hepatol 1993; 17 (3): 353–8.
27. Fiaccadori F, Pedretti G, Pasetti G et al. Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical study. Clin Invest 1993; 71 (7): 579–84.
28. Фомин В.В. Свойства антагониста альдостерона у петлевого диуретика: случайность или необходимость? Справочник поликлинического врача. 2010; c. 4.
29. Моисеев С.В. Клиническая эффективность и безопасность применения петлевого диуретика торасемида. Кардиология. 2006; c. 4.

А.А.Кириченко 

Кафедра терапии РМАПО, Москва